Topiroxostat versus allopurinol in patients with chronic heart failure complicated by hyperuricemia: A prospective, randomized, open-label, blinded-end-point clinical trial

BACKGROUND: The benefits of xanthine oxidase inhibitors to chronic heart failure (CHF) patients is controversial. We investigated the beneficial effects of a novel xanthine oxidoreductase inhibitor, topiroxostat, in patients with CHF and hyperuricemia (HU), in comparison to allopurinol. METHODS AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakuma, Masashi, Toyoda, Shigeru, Arikawa, Takuo, Koyabu, Yota, Kato, Toru, Adachi, Taichi, Suwa, Hideaki, Narita, Jun-ichi, Anraku, Koetsu, Ishimura, Kimihiko, Yamauchi, Fumitake, Sato, Yasunori, Inoue, Teruo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789120/
https://www.ncbi.nlm.nih.gov/pubmed/35077456
http://dx.doi.org/10.1371/journal.pone.0261445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789120/
https://www.ncbi.nlm.nih.gov/pubmed/35077456
http://dx.doi.org/10.1371/journal.pone.0261445

Ejemplares similares